You’ve identified your product as a candidate for approval via the 505(b)(2) pathway and completed a successful pre-IND meeting. What comes next?

In part two of this webinar series on the 505(b)(2) pathway, Ken delves deeper into IND-enabling activities including CMC, toxicology and PK/PD. Discover tips for harnessing creativity to reference the right data, design and conduct the right studies and get your program to the clinic faster.

Featured Speaker

Kenneth V. Phelps

President & Founder
Camargo

Ken Phelps is co-founder and president of Camargo. He has over 40 years of industry experience, including a number of executive-level positions in areas such as quality control, project management and regulatory, clinical and medical affairs.

NOW AVAILABLE ON-DEMAND

Register now for this webinar